|MDACC Study No:||2014-0058 (clinicaltrials.gov NCT No: NCT02039726)|
|Title:||A Phase 3 Open-Label Randomized Study of Quizartinib (AC220) Monotherapy versus Salvage Chemotherapy in Subjects with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Refractory to or Relapsed After First-Line Treatment with or without Hematopoietic Stem Cell Transplantation (HSCT) Consolidation|
|Principal Investigator:||Jorge Cortes|
|Study Description:||The goal of this clinical research study is to compare the effects of |
quizartinib to those of standard chemotherapy in patients with AML. The safety
of these drugs will also be studied.